Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration

Abstract Neurodegenerative disorders are characterized by the presence of inflammation in areas with neuronal cell death and a regional increase in iron that exceeds what occurs during normal aging. The inflammatory process accompanying the neuronal degeneration involves glial cells of the central nervous system (CNS) and monocytes of the circulation that migrate into the CNS while transforming into phagocytic macrophages. This review outlines the possible mechanisms responsible for deposition of iron in neurodegenerative disorders with a main emphasis on how iron-containing monocytes may migrate into the CNS, transform into macrophages, and die out subsequently to their phagocytosis of damaged and dying neuronal cells. The dying macrophages may in turn release their iron, which enters the pool of labile iron to catalytically promote formation of free-radical-mediated stress and oxidative damage to adjacent cells, including neurons. Healthy neurons may also chronically acquire iron from the extracellular space as another principle mechanism for oxidative stress-mediated damage. Pharmacological handling of monocyte migration into the CNS combined with chelators that neutralize the effects of extracellular iron occurring due to the release from dying macrophages as well as intraneuronal chelation may denote good possibilities for reducing the deleterious consequences of iron deposition in the CNS.

[1]  Katsuhide Ito,et al.  Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases , 1995, Journal of the Neurological Sciences.

[2]  Y. Imai,et al.  Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors , 2001, The Journal of Neuroscience.

[3]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[4]  J. Bijlsma,et al.  Synovium in haemophilic arthropathy , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  A. McKinney,et al.  Proton MR spectroscopy in Wilson disease: analysis of 36 cases. , 2005, AJNR. American journal of neuroradiology.

[6]  E. Morgan,et al.  Transferrin and Iron Uptake by the Brain: Effects of Altered Iron Status , 1991, Journal of neurochemistry.

[7]  B. Gwag,et al.  Iron mediates endothelial cell damage and blood-brain barrier opening in the hippocampus after transient forebrain ischemia in rats , 2011, Experimental & Molecular Medicine.

[8]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[9]  J. Connor,et al.  Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains , 1997, Neuroscience.

[10]  R. Ferrante,et al.  Huntington's disease: progress and potential in the field , 2007, Expert opinion on investigational drugs.

[11]  M. Bradbury Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.

[12]  J. Andersen,et al.  Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? , 2010, Journal of neurochemistry.

[13]  Wei Zhang,et al.  Intracellular metal ion chelators inhibit TNFalpha-induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. , 2003, Free radical biology & medicine.

[14]  Yinghe Hu,et al.  Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration , 2012, Translational Neurodegeneration.

[15]  G. Gerhard,et al.  Perspective: Atherosclerosis: a manifestation of chronic iron toxicity? , 2003 .

[16]  J. Growdon,et al.  Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.

[17]  A. Tolkovsky,et al.  Inhibition of Microglial Phagocytosis Is Sufficient To Prevent Inflammatory Neuronal Death , 2011, The Journal of Immunology.

[18]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[19]  J. Araujo,et al.  Iron overload augments the development of atherosclerotic lesions in rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[20]  H. Schumacher Arthropathy in hemochromatosis. , 1998, Hospital practice.

[21]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.

[22]  A. Suzumura Neuron-microglia interaction in neuroinflammation. , 2013, Current protein & peptide science.

[23]  J. Zimmer,et al.  Population control of resident and immigrant microglia by mitosis and apoptosis. , 2007, The American journal of pathology.

[24]  D. Mann,et al.  Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease , 2002, Neuroscience Letters.

[25]  G. Bing,et al.  Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.

[26]  Z. Qian,et al.  Role of hepcidin in murine brain iron metabolism , 2009, Cellular and Molecular Life Sciences.

[27]  F. Visseren,et al.  Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration: Iron and monocyte-endothelial cell interactions. , 2009, Atherosclerosis.

[28]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[29]  Rudi Balling,et al.  The hallmarks of Parkinson's disease , 2013, The FEBS journal.

[30]  H. Schumacher,et al.  The Arthropathy of Hemochromatosis , 1988, Annals of the New York Academy of Sciences.

[31]  E. Vichinsky,et al.  Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. , 2013, American journal of physical medicine & rehabilitation.

[32]  P. Carvey,et al.  6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.

[33]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[34]  H. Schumacher HEMOCHROMATOSIS AND ARTHRITIS. , 1964, Arthritis and rheumatism.

[35]  M. Schwartz,et al.  Systemic inflammatory cells fight off neurodegenerative disease , 2010, Nature Reviews Neurology.

[36]  J. del Valle,et al.  Blood-brain barrier disruption in the striatum of rats treated with 3-nitropropionic acid. , 2009, Neurotoxicology.

[37]  U. Bonuccelli,et al.  New pharmacologic horizons in the treatment of Parkinson disease , 2006, Neurology.

[38]  Elizabeth C. Theil Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.

[39]  Victoria Tapia,et al.  Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells , 2013, Journal of neurochemistry.

[40]  D. Ogilvie-Harris,et al.  Synovial iron deposition in osteoarthritis and rheumatoid arthritis. , 1980, The Journal of rheumatology.

[41]  C. Humpel,et al.  Primary rat monocytes migrate through a BCEC-monolayer and express microglia-markers at the basolateral side , 2007, Brain Research Bulletin.

[42]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[43]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[44]  Khadija Iqbal,et al.  Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia , 2004, Acta Neuropathologica.

[45]  E. Haller,et al.  Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS , 2007, PloS one.

[46]  E. Morgan,et al.  Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.

[47]  T. Moos,et al.  The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease , 1999, Neuroscience.

[48]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[49]  G. Hansson Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. , 2009, Atherosclerosis.

[50]  M. Shingu,et al.  Iron-binding proteins and free iron in synovial fluids of rheumatoid arthritis patients , 1989, Clinical Rheumatology.

[51]  Miikka Vikkula,et al.  Cerebrovascular disorders: molecular insights and therapeutic opportunities , 2011, Nature Neuroscience.

[52]  W. Hagen,et al.  The catalytic center of ferritin regulates iron storage via Fe(II)-Fe(III) displacement. , 2012, Nature chemical biology.

[53]  C. Quintana,et al.  Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.

[54]  J. Lichota,et al.  Heterogenous distribution of ferroportin-containing neurons in mouse brain , 2011, BioMetals.

[55]  P. Anand,et al.  COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord , 2006, BMC neurology.

[56]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[57]  G. Arendash,et al.  Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex , 1995, Neuroscience.

[58]  Tzong-Shyuan Lee,et al.  Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. , 1999, Circulation.

[59]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[60]  T. J. Cunningham,et al.  Differential immunochemical markers reveal the normal distribution of brain macrophages and microglia in the developing rat brain , 1991, The Journal of comparative neurology.

[61]  N. Suttle Copper imbalances in ruminants and humans: unexpected common ground. , 2012, Advances in nutrition.

[62]  H. Rowley,et al.  Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. , 2006, AJNR. American journal of neuroradiology.

[63]  Dale E. Bredesen,et al.  Cell death in the nervous system , 2006, Nature.

[64]  M. Muckenthaler,et al.  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.

[65]  M. Sawada,et al.  Role of cytokines in inflammatory process in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[66]  Wei-jian Zhang,et al.  The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice , 2010, Experimental biology and medicine.

[67]  D. Dexter,et al.  Chelating agents for neurodegenerative diseases. , 2012, Current medicinal chemistry.

[68]  P. Riederer,et al.  Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.

[69]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[70]  Marek Luczkowski,et al.  Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases) , 2012 .

[71]  Brian F. Corbett,et al.  Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[72]  U. Dirnagl,et al.  Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  Ramandeep Singh,et al.  Current therapeutic strategy in Alzheimer's disease. , 2012, European review for medical and pharmacological sciences.

[74]  Dean Y. Li,et al.  Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. , 2010, The Journal of clinical investigation.

[75]  R. Ransohoff,et al.  Heterogeneity of CNS myeloid cells and their roles in neurodegeneration , 2011, Nature Neuroscience.

[76]  S. Gandhi,et al.  Mechanism of Oxidative Stress in Neurodegeneration , 2012, Oxidative medicine and cellular longevity.

[77]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[78]  P. Mecocci,et al.  Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[79]  F. Codazzi,et al.  Iron uptake in quiescent and inflammation-activated astrocytes: A potentially neuroprotective control of iron burden , 2013, Biochimica et biophysica acta.

[80]  Alessandra Solari,et al.  Iron‐related MRI images in patients with pantothenate kinase–associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial , 2011, Movement disorders : official journal of the Movement Disorder Society.

[81]  P. Sanberg,et al.  Neurovascular aspects of amyotrophic lateral sclerosis. , 2012, International review of neurobiology.

[82]  Kaan E. Biron,et al.  Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization , 2013, Scientific Reports.

[83]  A. Mahadevan,et al.  Elevated Oxidative Stress and Decreased Antioxidant Function in the Human Hippocampus and Frontal Cortex with Increasing Age: Implications for Neurodegeneration in Alzheimer’s Disease , 2012, Neurochemical Research.

[84]  Jeff H. Duyn,et al.  Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology , 2012, PloS one.

[85]  M. D. Mossalayi,et al.  Nitric oxide production by human monocytes: evidence for a role of CD23. , 1995, Immunology today.

[86]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[87]  K. Pantopoulos,et al.  Iron metabolism and toxicity. , 2005, Toxicology and applied pharmacology.

[88]  C. Chen Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. , 2011, Chang Gung medical journal.

[89]  C. Morris,et al.  Relationship between iron deposits and tissue damage in the synovium: an ultrastructural study. , 1986, Annals of the rheumatic diseases.

[90]  A. Gregory,et al.  Genetics of Neurodegeneration with Brain Iron Accumulation , 2011, Current neurology and neuroscience reports.

[91]  J. Cano,et al.  Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons , 2007, Journal of neurochemistry.

[92]  Kaan E. Biron,et al.  Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer's Disease , 2011, PloS one.

[93]  S. Mandel,et al.  The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice , 2007, Journal of Neural Transmission.

[94]  F. Visseren,et al.  Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[95]  P. Mcgeer,et al.  Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. , 2005, Current Alzheimer research.

[96]  J. Connor,et al.  Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain , 1993, The Journal of comparative neurology.

[97]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[98]  M. Linder The relationship of copper to DNA damage and damage prevention in humans. , 2012, Mutation research.

[99]  B. Gwag,et al.  Blood-derived iron mediates free radical production and neuronal death in the hippocampal CA1 area following transient forebrain ischemia in rat , 2011, Acta Neuropathologica.

[100]  Andrew G. Webb,et al.  Elevated brain iron is independent from atrophy in Huntington's Disease , 2012, NeuroImage.

[101]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[102]  Ogilvie-Harris Dj,et al.  Synovial iron deposition in osteoarthritis and rheumatoid arthritis. , 1980 .

[103]  H. Nazer,et al.  Wilson's Disease. , 1991, Annals of Saudi medicine.

[104]  D. Reif,et al.  Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.

[105]  Z. Sheng,et al.  Expression of the iron transporter ferroportin in synaptic vesicles and the blood–brain barrier , 2004, Brain Research.

[106]  Guy C. Brown,et al.  Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons , 2010, Molecular Neurobiology.

[107]  C. Moussa,et al.  Inflammation in the early stages of neurodegenerative pathology , 2011, Journal of Neuroimmunology.

[108]  P. Levitt,et al.  Brain macrophages and microglia respond differently to lesions of the developing and adult visual system , 1991, The Journal of comparative neurology.

[109]  D. D. Di Monte,et al.  Redox cycling of the herbicide paraquat in microglial cultures. , 2005, Brain research. Molecular brain research.

[110]  L. Thal,et al.  A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. , 2000, Neurology.

[111]  R. Rodnitzky Upcoming treatments in Parkinson's disease, including gene therapy. , 2012, Parkinsonism & Related Disorders.

[112]  Gary Lynch,et al.  Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.

[113]  J. Cano,et al.  Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.

[114]  M. Parihar,et al.  Reduction of lipid peroxidation in different brain regions by a combination of α-tocopherol and ascorbic acid , 2005, Journal of Neural Transmission.

[115]  P. Dallman,et al.  Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency. , 1977, The Journal of nutrition.

[116]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[117]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[118]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[119]  B. Halliwell,et al.  The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. , 2005, Free radical biology & medicine.

[120]  R. Hider,et al.  The potential application of iron chelators for the treatment of neurodegenerative diseases. , 2011, Metallomics : integrated biometal science.

[121]  R. Ransohoff,et al.  Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.

[122]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[123]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[124]  I. Tabas,et al.  Macrophage Apoptosis in Advanced Atherosclerosis , 2009, Annals of the New York Academy of Sciences.

[125]  Roberta J. Ward,et al.  Brain iron metabolism and its perturbation in neurological diseases , 2011, Journal of Neural Transmission.

[126]  G. Gerhard,et al.  Atherosclerosis: a manifestation of chronic iron toxicity? , 2003, Vascular medicine.

[127]  B. Gallois,et al.  Mutant Ferritin L-chains That Cause Neurodegeneration Act in a Dominant-negative Manner to Reduce Ferritin Iron Incorporation* , 2010, The Journal of Biological Chemistry.

[128]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[129]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[130]  A. Koeppen,et al.  Iron in the Hallervorden-Spatz syndrome. , 2001, Pediatric neurology.

[131]  M. Youdim,et al.  Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.

[132]  R. Yokel,et al.  The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. , 1996, Toxicology.

[133]  S. Koppula,et al.  Reactive Oxygen Species and Inhibitors of Inflammatory Enzymes, NADPH Oxidase, and iNOS in Experimental Models of Parkinson's Disease , 2012, Mediators of inflammation.

[134]  A. Sun,et al.  Cytotoxicity of paraquat in microglial cells: Involvement of PKCδ- and ERK1/2-dependent NADPH oxidase , 2007, Brain Research.

[135]  L. Della Corte,et al.  Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration , 2011, Journal of Neural Transmission.

[136]  B. Ghetti,et al.  Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice , 2008, The Journal of Neuroscience.

[137]  Wei Zhang,et al.  The role of microglia in paraquat-induced dopaminergic neurotoxicity. , 2005, Antioxidants & redox signaling.

[138]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[139]  S. Hayflick Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.

[140]  M. J. Bández,et al.  Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. , 2012, Neurotoxicology.

[141]  A. Sun,et al.  Oxidative and Inflammatory Pathways in Parkinson’s Disease , 2008, Neurochemical Research.

[142]  R. El-Bachá,et al.  Brain rust: Recent discoveries on the role of oxidative stress in neurodegenerative diseases , 2012, Nutritional neuroscience.

[143]  E. Ling,et al.  Iron and Iron Regulatory Proteins in Amoeboid Microglial Cells Are Linked to Oligodendrocyte Death in Hypoxic Neonatal Rat Periventricular White Matter through Production of Proinflammatory Cytokines and Reactive Oxygen/Nitrogen Species , 2011, The Journal of Neuroscience.

[144]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[145]  D. Ruano,et al.  Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic , 2008, The Journal of Neuroscience.

[146]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[147]  J. Kehrer The Haber-Weiss reaction and mechanisms of toxicity. , 2000, Toxicology.

[148]  M. Davies,et al.  Direct Detection and Quantification of Transition Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of Elevated Levels of Iron and Copper , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[149]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[150]  C. Cunningham Microglia and neurodegeneration: The role of systemic inflammation , 2013, Glia.

[151]  J. Haorah,et al.  Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.

[152]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[153]  C. Morris,et al.  Iron in joint inflammation. , 1993, Annals of the rheumatic diseases.

[154]  E. Fibach,et al.  Flow cytometry measurement of the labile iron pool in human hematopoietic cells , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[155]  D. Girelli,et al.  Differential regulation of iron homeostasis during human macrophage polarized activation , 2010, European journal of immunology.

[156]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[157]  C. Palmer,et al.  Cellular distribution of ferritin subunits in postnatal rat brain , 1998, The Journal of comparative neurology.

[158]  R J Simpson,et al.  A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.

[159]  T. Rouault,et al.  Iron metabolism in the CNS: implications for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[160]  H. Lassmann Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease , 2011, Journal of Neural Transmission.

[161]  R. Bennett,et al.  Synovial iron deposition in rheumatoid arthritis. , 1973, Arthritis and rheumatism.

[162]  J. Connor,et al.  Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat , 2001, Journal of neuroscience research.

[163]  M. Locati,et al.  Iron levels in polarized macrophages: regulation of immunity and autoimmunity. , 2012, Autoimmunity reviews.

[164]  S. Hirai,et al.  Activated microglia cause superoxide-mediated release of iron from ferritin , 1995, Neuroscience Letters.

[165]  A. Luster,et al.  Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.

[166]  E. Hirsch Altered regulation of iron transport and storage in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[167]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[168]  N. Van Rooijen,et al.  Ulcerative colitis exacerbates lipopolysaccharide‐induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease , 2010, Journal of neurochemistry.

[169]  E. Morgan,et al.  Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. , 2000, Cellular and molecular biology.

[170]  D. Sparks,et al.  Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.

[171]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[172]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.